Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $50.30

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have received a consensus rating of “Moderate Buy” from the eleven research firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $50.30.

Several brokerages recently commented on ANAB. Truist Financial lifted their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a research report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. upped their target price on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th.

AnaptysBio Stock Performance

ANAB opened at $35.90 on Tuesday. The business’s 50-day simple moving average is $33.50 and its 200-day simple moving average is $27.05. The company has a market cap of $980.75 million, a P/E ratio of -5.85 and a beta of -0.25. AnaptysBio has a one year low of $13.36 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The company had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. As a group, analysts predict that AnaptysBio will post -6.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were acquired at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the acquisition, the insider now owns 7,794,996 shares in the company, valued at approximately $284,517,354. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of AnaptysBio stock in a transaction dated Wednesday, August 14th. The stock was bought at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the purchase, the insider now owns 7,794,996 shares of the company’s stock, valued at $284,517,354. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $35.00, for a total transaction of $52,500.00. Following the transaction, the insider now owns 11,618 shares in the company, valued at $406,630. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,400 shares of company stock valued at $449,244. 33.70% of the stock is owned by company insiders.

Institutional Trading of AnaptysBio

Institutional investors have recently added to or reduced their stakes in the stock. Trexquant Investment LP boosted its position in shares of AnaptysBio by 107.6% in the 4th quarter. Trexquant Investment LP now owns 21,832 shares of the biotechnology company’s stock worth $468,000 after buying an additional 11,318 shares in the last quarter. Quest Partners LLC purchased a new stake in AnaptysBio in the 4th quarter valued at about $119,000. Franklin Resources Inc. raised its stake in AnaptysBio by 22.7% during the fourth quarter. Franklin Resources Inc. now owns 405,115 shares of the biotechnology company’s stock worth $8,678,000 after purchasing an additional 75,025 shares during the period. First Light Asset Management LLC increased its stake in AnaptysBio by 56.4% during the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after acquiring an additional 446,372 shares during the last quarter. Finally, Great Point Partners LLC raised its stake in shares of AnaptysBio by 9.2% in the 4th quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock valued at $20,927,000 after acquiring an additional 82,648 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.